MAIA BiotechnologyNYSE American: MAIA

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy.

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer.

MAIA Biotechnology will be speaking at the BIO International Convention 2024 in Chicago.

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.

Lead asset THIO has a unique telomere-targeting mechanism and has reported impressive preliminary results in NSCLC. THIO's 90%+ disease control rate in second- and third-line NSCLC is an improvement over current standard of care. Plans to pursue accelerated approval in NSCLC in 2025 and has the potential to become a new standard of care.

MAIA Biotechnology, Inc. (MAIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 2023.

MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The first two patients in the trial have achieved continued survival at 10 and 11 months following the start of treatment. MAIA has enough cash to make it to an update from the trial, but another cash raise could be ahead.